X

News

"Update in Health Status in the Magallanes Region: Problems and Challenges"

On April 28th, Virbac-Centrovet organized a Technical Workshop called “Update in Health Status in the Magallanes Region”, which was held at the Diego de Almagro Hotel, in Punta Arenas. On this occasion various technical talks were given, all of them related to different aspects of the sanitary status of the Magallanes region. The speakers were Claudio Araneda (R & D Pharmaceutical Manager, Virbac-Centrovet), Jaime Tobar (R & D Biological Manager, Virbac-Centrovet), Claudia Gatica (Assistant Marketing Manager, Skretting Chile), Ivan Ñancufil (head of Health in Seawater, Salmones Magallanes) and Patricio Bustos (General Manager, ADL Diagnostics Chile Ltda.)

Leer más...

Virbac - Centrovet participates in a successful Congress of Veterinary Medicine in VIII Region

Between 17 and 18 June this year, the VI INTERNATIONAL SYMPOSIUM ON CARDIOLOGY AND VETERINARY EMERGENCY took place at the Gran Hotel Termas de Chillan, organized by MEVEPA (Association of Small Animals Veterinary Specialists) of the VIII Region, which brought together more than 100 veterinarians nationwide. This time, the exhibits were dominated by two prominent veterinarians: Dr. Carlos Mucha (Argentina), who is a specialist in the area of Veterinary Cardiology; and Dr. Cesar Villalta (Chile), who serves in the area of Integrative Medicine, Cardiology and Anesthesiology. As in previous years, Virbac-Centrovet actively participated throughout the event, providing valuable technical information on the nutritional line HPM, plus gifts and souvenirs to all participants.

Leer más...

Integral Vaccination: The Key to Success

t is well known in the industry that our laboratory has registered an SRS oral vaccine, that optimizes the protection against SRS, which is supported by productive information and scientific publications. Thanks to this study, our team was able to estimate which is the impact of this product in reducing medication. The extension of the analysis to the model immunization/booster made in the same period, shows results that continue to set positive trend. The centers vaccinated with Blueguard® injectable and an oral booster aren´t medicated until after 3000 UTA on average since the injectable vaccine (unlike other providers, limited to 1921 UTA), meaning on average 3 months extra without medication. This means in practical terms that on average the first medication occurs after the period of protection of the injectable vaccine with oral booster, being therefore an effective strategy for reducing medication. Also, the number of centers unmedicated between August 2015 and April 2016 amounted to 63%, unlike 42% of centers identified as having been vaccinated with products different to Blueguard®. That means the strategy Blueguard® injection and oral is a 33% more effective in removing medication.

Leer más...

Analysis of field indicators that supports the vaccination strategy as an effective method for reducing medication.

In order to provide field data about the performance of our vaccines in order to reduce medication, our laboratory has joined forces with our customers, gathering information of medication consumption based in different vaccination strategies. The results of this analysis confirm that it is possible to drastically reduce medication in culture, due to a good vaccination practice. The analysis was focused on the period August 2015-April 2016, with the aim to consider the summer period, which is the period with the highest incidence of SRS, and use of medicated for this cause.

Leer más...

Advantages of an Encapsulated Oral Vaccine against ISA virus

In order to evaluate the efficacy in inducing immunity, Virbac-Centrovet together with the Faculty of Veterinary and Animal Sciences at the University of Chile and the US company Advanced BioNutrition, conducted a study to evaluate in vivo formulations containing different components of a recombinant oral vaccine against a Chilean highly virulent isolate (HPR7b).

 

Infectious Salmon Anemia (ISA) is a systemic disease caused by a orthomyxoviruses, which has a significant economic impact on the production of Atlantic salmon (Salmo salar).

 

To avoid losses caused by this disease, prophylactic effective treatments have been sought to reduce the effects of ISA. One of such treatment has been the development of vaccines for intraperitoneal (IP) application based in emulsions containing either the inactivated organism or fractions thereof, produced by recombinant DNA technology.

 

Injectable vaccines have many advantages, however they present some practical limitations, since when applied one by one, they cause stress in fish, leaving them susceptible to other infectious diseases due to the injection process and associated to the handling. In addition, there are few scientific articles describing the mode of action and efficacy of these vaccines.

 

The study was conducted at the premises of Virbac-Centrovet (Santiago, Chile), using Atlantic salmon with an average weight of 40 g in 100 L tanks and groups of 55 fish at a density of 50 kg / m3.

 

The vaccine was developed using recombinant DNA technology in Saccharomyces cerevisiae. Fish were fed with a diet containing the vaccine in a final concentration equivalent to 6 mg vaccine / fish / day for 10 days. For the experimental challenge, ISAv virulent strain (strain HPR7b) isolated from an outbreak in a farming center in the region of Los Lagos was used.

 

The study showed that oral vaccination is able to protect the Atlantic salmon against a variant of ISA virus highly virulent and oral vaccination is also correlated with the induction of specific IgM antibodies.

 

According to the results of this study, it can be said that oral vaccines are similar in terms of protection to an IP vaccine; changing the kinetics of development of immunity, which was established in 300 UTA for oral vaccine and UTA 600 for the injectable vaccine. This has a high correlation with the protection provided by these vaccines, which has been measured in some recent cases of vaccinated fish in the sea, which have been challenged with the ISA virus.

 

It can be said that the great advantage of oral vaccination is that it allows the application of continuous reinforcements of it, maintaining high active immunity, extending the protection of injectable vaccines effectively until the harvest.

 

In practice it has been observed that injectable vaccines protect against pathogens until 1800-2000 UTA, corresponding to about 700-800 grams in Atlantic salmon. Oral vaccines allow extending this protection to reach 5-6 kg. In the experience of Virbac-Centrovet, oral vaccines that have been developed for ISA, SRS and IPN have shown in practice that protection is similar to that of injectable vaccines. Combining these two advantages, oral vaccines protect effectively until the harvest. Besides of being a tool to control outbreaks, they reduce significantly the use of antibiotics, delivering additional value to the production chain.

Leer más...